Compare Cassava Sciences Inc (FLNA) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Under Armour Inc Class A — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Under Armour Inc Class A trades at $7.21 (market cap $2.89B). The key difference: Under Armour Inc Class A is far larger — about 54.4× Cassava Sciences Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | UAA | |
|---|---|---|
Market Cap | $53.14M | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $8.14 |
52-Week Low | $1.09 | $4.17 |
Enterprise Value | -$33.43M | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Under Armour (UAA) trades at $7.19, up 8.77% in the last session, with a bullish technical signal from moving averages and oscillators. The stock shows mixed fundamentals, with a negative net income margin of -9.98% and ROE of -30% for 2025, but beats earnings expectations in recent quarters. Cash flow trends are volatile, with a net outflow of $361.87M in 2025, while revenue declined to $5.16B. Analyst sentiment is cautious, with a consensus price target of $5.96 below the current price, and 58.11% hold ratings.
The outlook for UAA is challenged by weak North American sales and margin pressure, offset by international growth. Investment opportunity hinges on execution of a full-price strategy and cost control, but risks include consumer resistance and macroeconomic uncertainty. With the stock trading above the consensus target, near-term upside may be limited despite technical strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
